HilleVax (HilleVax) Receivables Turnover : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is HilleVax Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. HilleVax's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. HilleVax's average Accounts Receivable for the three months ended in Mar. 2024 was $0.00 Mil.

HilleVax Receivables Turnover Historical Data

The historical data trend for HilleVax's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Receivables Turnover Chart

HilleVax Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

HilleVax Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of HilleVax's Receivables Turnover

For the Biotechnology subindustry, HilleVax's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HilleVax's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HilleVax's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where HilleVax's Receivables Turnover falls into.

HilleVax Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

HilleVax's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

HilleVax's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

HilleVax (NAS:HLVX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

HilleVax Receivables Turnover Related Terms

Thank you for viewing the detailed overview of HilleVax's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

HilleVax (HilleVax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 State Street, Suite 100 - No. 9995, Boston, MA, USA, 02109

Website

https://www.hillevax.com

HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Executives

Astrid Borkowski	officer: Chief Medical Officer	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Shane Maltbie	officer: Chief Financial Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Frazier Life Sciences X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Fhmls X, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda	director	C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc.	10 percent owner	75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu	director	ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aditya Kohli	director, officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
David A Socks	officer: CFO & Chief Business Officer	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668